Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant ± Lapatinib ± Aromatase Inhibitor in metastatic breast cancer progressing after aromatase inhibitor therapy
2007-006031-30Phase 3Active
- Sponsor
- Consorzio Oncotech
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of fulvestrant and lapatinib in breast cancer (4 arms), sponsored by Consorzio Oncotech. Primary endpoints: Progression-free survival, Time to progression and 1 more. Started Jan 2009; status: active.
02
Drugs
fulvestrantlapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-006031-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006031-30.